Recombinant Human Clusterin Protein

重组人Clusterin alpha chain蛋白 | 重组人类丛集蛋白

40 | AAG4 | Aging-associated gene 4 protein | aging-associated protein 4 | Apo-J | APOJ | ApoJalpha | ApoJbeta | Apolipoprotein J | CLI | CLU | CLUS_HUMAN | Clusterin | Clusterin alpha chain | Complement cytolysis inhibitor | Complement cytolysis inhibito

rp144473-50μg

50μg

无动物源

≥90%(SDS-PAGE)

＞90%(SDS-PAGE)

Purity >90% SDS-PAGE. Function Isoform 1 functions as extracellular chaperone that prevents aggregation of nonnative proteins. Prevents stress-induced aggregation of blood plasma proteins. Inhibits formation of amyloid fibrils by APP, APOC2, B2M, CALCA, CSN3, SNCA and aggregation-prone LYZ variants (in vitro). Does not require ATP. Maintains partially unfolded proteins in a state appropriate for subsequent refolding by other chaperones, such as HSPA8/HSC70. Does not refold proteins by itself. Binding to cell surface receptors triggers internalization of the chaperone-client complex and subsequent lysosomal or proteasomal degradation. Secreted isoform 1 protects cells against apoptosis and against cytolysis by complement. Intracellular isoforms interact with ubiquitin and SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complexes and promote the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes proteasomal degradation of COMMD1 and IKBKB. Modulates NF-kappa-B transcriptional activity. Nuclear isoforms promote apoptosis. Mitochondrial isoforms suppress BAX-dependent release of cytochrome c into the cytoplasm and inhibit apoptosis. Plays a role in the regulation of cell proliferation. Post-translational Isoform 1 is proteolytically cleaved on its way through the secretory system, probably within the Golgi lumen. Polyubiquitinated, leading to proteasomal degradation. Heavily N-glycosylated. About 30% of the protein mass is comprised of complex N-linked carbohydrate.

Measured by its ability to induce clustering of Caki‑2 human clear cell carcinoma epithelial cells.

重组表达

47 kDa

C-His

36.2 kDa, under reducing conditions; 60.7 kDa, under non-reducing conditions.

HEK293 Accession #: P10909-1 | HEK293

<0.1 EU/μg

人(Human)

23-449 aa

DQTVSDNELQEMSNQGSKYVNKEIQNAVNGVKQIKTLIEKTNEERKTLLSNLEEAKKKKEDALNETRESETKLKELPGVCNETMMALWEECKPCLKQTCMKFYARVCRSGSGLVGRQLEEFLNQSSPFYFWMNGDRIDSLLENDRQQTHMLDVMQDHFSRASSIIDELFQDRFFTREPQDTYHYLPFSLPHRRPHFFFPKSRIVRSLMPFSPYEPLNFHAMFQPFLEMIHEAQQAMDIHFHSPAFQHPPTEFIREGDDDRTVCREIRHNSTGCLRMKDQCDKCREILSVDCSTNNPSQAKLRRELDESLQVAERLTRKYNELLKSYQWKMLNTSSLLEQLNEQFNWVSRLANLTQGEDQYYLRVTTVASHTSDSDVPSGVTEVVVKLFDSDPITVTVPVEVSRKNPKFMETVAEKALQEYRKKHREEHHHHHH

Yes

Yes